Promising data in the clinical trial with HDP-101 in multiple myeloma, including a complete remission in one patient; study progressing well First approvals for clinical trial with ATAC candidate HDP-102 received; study start soon Financial figures in line with plan with improved operating result and lower cash requirements Payment of USD 20 million from HealthCare […]
HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment Heidelberg Pharma extends cash runway into 2027 Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed […]
Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, […]
Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]
First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the […]
